GPS-like technology helps diagnose prostate tumors

May 3, 2013 by Delthia Ricks

The lead investigator of a way to obtain images of prostate tumors and accurately diagnose them said Thursday that the new technology is the medical equivalent of a global positioning system for the prostate gland.

North Shore-Long Island Jewish Health system only institution other than the National Institutes of Health in Bethesda, Md., to use the new , Dr. Art Rastinehad of North Shore-LIJ said Thursday at a news conference.

Current biopsy testing relies on decades-old technology, which misses a vast number of cancers and delays treatment for many men, Rastinehad said.

"Biopsies have been performed the same way for the last 30 years," said Rastinehad, who noted the current technique involves a and .

If the cancer grows outside what can be seen on an ultrasound, the tumor can be missed, Rastinehad said, adding that standard technology evaluates less than half a percent of the .

He and his collaborators at the NIH have been testing a new system, which they helped to develop. It is loosely called a fusion biopsy, Rastinehad said, because it involves both MRI and ultrasound imaging.

Additionally, Rastinehad said, a so-called field generator, similar to a , is placed over a patient's hip to guide the entire biopsy process. The MRI and ultrasound images, meanwhile, are overlaid in real-time, providing a more comprehensive, multidimensional view of the gland.

"Our goal is to have a more image-based standard of care for biopsying prostate cancer, but we are still building a body of evidence," Rastinehad said.

Developed by Invivo, a division of Philips Healthcare, the entire system is called UroNav.

Rastinehad and his NIH colleagues have tested it on more than 900 men and think that it provides multiple advantages over the current standard. The approved the system for widespread use last month. More than 240,000 new cases of prostate cancer are diagnosed annually nationwide. About 30,000 men die of the disease.

Rich Bolton, 61, a retired financial executive, underwent a biopsy with the system in January as part of Rastinehad's research.

Bolton, who lives in Point Lookout, N.Y., said he had routine screenings for involving the prostate specific antigen blood test which on more than one occasion had come back with a high reading.

"I had been watching my PSA numbers starting back in December of 2007," Bolton said. "The numbers started to rise and I got a prostate biopsy and it came back negative.

"My PSA rose again in 2009," Bolton said. "I have a family member who is a urological surgeon in Kentucky and he was a bit concerned but made sure I stayed on top of it."

Bolton got a second biopsy-but that also came back negative.

His doctor put him on Proscar, a drug that could address a high PSA not due to cancer. But as time passed, the PSA remained high, which prompted his Garden City physician to recommend Rastinehad, whose research into precision imaging was gaining notoriety on Long Island.

Bolton's fusion revealed an advanced cancer.

"Dr. Rastinehad's instruments have GPS in them so he found the cancer," Bolton said.

"I am stage 4, but I probably wouldn't have known this for another couple of years."

"I had a full body scan and the cancer is really isolated. It's manageable," Bolton said. "They caught it late, but they caught it while it is treatable."

Explore further: PSA test valuable in predicting biopsy need, low-risk prostate cancer

Related Stories

PSA test valuable in predicting biopsy need, low-risk prostate cancer

October 21, 2011
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. ...

When rising PSA means prostate cancer is in patient's future

May 18, 2011
A man's rising PSA (prostate-specific antigen) level over several years – which had been seen as a possible warning sign of prostate cancer – has recently come under fire as a screening test because it sometimes ...

Doctors can now detect hard-to-diagnose prostate cancer

August 9, 2012
Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more ...

Prostate cancer now detectable by imaging-guided biopsy

December 10, 2012
Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.